CDTX Overview
Upcoming Projects (CDTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CDTX)
-
Discussing novel therapies for influenza and associated exposure-response analysis.
Tickers: CDTX, VIR
Executed On: Feb 19, 2025 at 11:30 AM EST -
A Second Look: Discussing the potential of Cidara's once-weekly echinocandin, Rezzayo (rezafungin acetate) for the treatment and prevention of serious fungal infections
Ticker: CDTX
Executed On: Mar 28, 2024 at 12:30 PM EDT -
Discussing the potential of Cidara's once-weekly echinocandin, rezafungin for the treatment and prevention of serious fungal infections
Ticker: CDTX
Executed On: Mar 07, 2023 at 03:30 PM EST
Upcoming & Overdue Catalysts (CDTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CDTX)
-
Topline Results from Cidara Therapeutics' (CDTX) Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
Ticker: CDTX
Occurred on: Mar 19, 2018 -
Cidara (CDTX) Phase 2 RADIANT Data Evaluating Topical CD101 in Yeast Infection (Vulvovaginal Candidiasis VVC)
Ticker: CDTX
Occurred on: Feb 21, 2017 -
Cidara Therapeutics plans to initiate a Phase 2 trial for CD101 IV in treating candidemia in the first half of 2016
Ticker: CDTX
Occurred on: Jun 09, 2016 -
Cidara recieves Orphan Drug Designation for novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis
Ticker: CDTX
Occurred on: Feb 10, 2016
Strategic Initiatives (CDTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
